Arrowhead Pharmaceuticals Inc

ARWR

Equity

ISIN null / Valor 32193461

NASDAQ (2025-11-21)

USD 40.45+6.20%

Arrowhead Pharmaceuticals Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Arrowhead Pharmaceuticals Inc. is a biopharmaceutical company engaged in the development of innovative drugs. The company focuses on leveraging its proprietary RNA interference (RNAi) technology to silence genes that cause diseases. A specific example of their work includes the clinical study of ARO-RAGE, a therapeutic candidate aimed at treating inflammatory lung diseases. This study is designed to assess the safety, tolerability, and pharmacokinetics of ARO-RAGE in both normal healthy volunteers and participants with inflammatory lung disease, indicating Arrowhead's commitment to addressing unmet medical needs in the respiratory disease area. The study is structured in two parts, with the initial phase testing the drug on healthy volunteers and the subsequent phase on patients with the targeted condition, showcasing the company's methodical approach to drug development and its focus on RNAi technology as a basis for its therapeutic innovations.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

For the third quarter of fiscal 2025, Arrowhead Pharmaceuticals reported revenue of $27.8 million, a significant increase from no revenue in the same period last year, highlighting progress in its commercial and partnership activities.

Increased Research and Development Expenses

Research and development expenses rose to $162.4 million in Q3 2025 compared to $152.4 million in Q3 2024, reflecting the company's intensified efforts in advancing its clinical programs and pipeline development.

Net Loss and Operating Expenses

The net loss attributable to Arrowhead Pharmaceuticals increased to $175.2 million for the quarter, up from $170.8 million in the previous year. Total operating expenses also grew to $193.3 million from $176.1 million year-over-year, driven by higher R&D and general administrative costs.

Strong Cash Position

As of June 30, 2025, Arrowhead maintained a robust cash position with total cash resources of $900.4 million, up from $681.0 million at the end of the previous fiscal year, ensuring ample financial support for ongoing and future clinical and regulatory activities.

Milestone Achievements and Collaborations

In the quarter, Arrowhead secured a $100 million milestone payment from Sarepta Therapeutics and signed a $130 million asset purchase agreement with Sanofi for the development and commercialization of plozasiran in Greater China, reinforcing its strategic partnerships and revenue streams.

Summarized from source with an LLMView Source

Key figures

121%1Y

35.6%3Y

-41.2%5Y

Performance

71.5%1Y

65.2%3Y

64.4%5Y

Volatility